Bayer earns FDA untitled letter for Nubeqa's 'attention-grabbing visuals'

30th April 2026 Uncategorised 0

The FDA has reprimanded Bayer for the “attention-grabbing visuals” and “frequent scene changes” in ads for the company’s prostate cancer drug Nubeqa.

More: Bayer earns FDA untitled letter for Nubeqa's 'attention-grabbing visuals'
Source: fierce